Claims for Patent: 10,981,952

Summary for Patent: 10,981,952

Title:	IBAT inhibitors for the treatment of liver diseases
Abstract:	The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.
Inventor(s):	Gillberg; Per-Goran (Molndal, SE), Graffner; Hans (Helsingborg, SE), Starke; Ingemar (Gothenburg, SE)
Assignee:	Albireo AB (Goteborg, SE)
Application Number:	16/737,742
Patent Claims:	1. A method for decreasing the concentration of serum bile acids in a subject in need thereof, comprising orally administering to the subject a therapeutically effective amount of an IBAT inhibitor, wherein the IBAT inhibitor is 1,1-dioxo-3,3-dibutyl-5-phenyl-7-methylthio-8-(N-{(R)-.alpha.-[N--((S)-1-- carboxypropyl)carbamoyl]-4-hydroxybenzyl}carbamoylmethoxy)-2,3,4,5-tetrahy- dro-1,2,5-benzothiadiazepine, or a pharmaceutically acceptable salt thereof; wherein the subject has a disease selected from the group consisting of: Alagilles syndrome (ALGS), progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis (PBC), liver fibrosis, non alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), intrahepatic cholestasis, extrahepatic cholestasis, and combinations thereof. 2. The method of claim 1, wherein the subject is a pediatric subject. 3. The method of claim 1, wherein the subject has PFIC. 4. The method of claim 1, wherein the subject has ALGS. 5. The method of claim 1, wherein the subject has intrahepatic cholestasis. 6. The method of claim 1, wherein the subject has extrahepatic cholestasis. 7. The method of claim 1, wherein the subject has pruritus as a comorbidity. 8. The method of claim 1, wherein the subject has pruritus as a symptom of the disease. 9. The method of claim 1, further comprising administering a therapeutically effective amount of a bile acid binder. 10. The method of claim 9, wherein the bile acid binder is a resin. 11. The method of claim 10, wherein the resin is selected from the group consisting of: cholestyramine, cholestipol, and colesevelam. 12. The method of claim 11, wherein the resin is cholestyramine, or a pharmaceutically acceptable salt thereof.